Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

DRUG: Nemolizumab
DRUG: Nemolizumab

Sponsor

Galderma R&D